問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

更新時間：2023-09-19

盧孟佑LU, MENG-YAO
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

盧孟佑

List

26Cases

2024-08-01 - 2031-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-03-31 - 2025-01-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2009-06-01 - 2011-08-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2026-02-23 - 2032-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-10-17 - 2028-12-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-12-01 - 2025-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-01-05 - 2026-09-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2017-01-20 - 2022-02-17

Phase III

A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

  • Condition/Disease

    Mature B-cell Non-Hodgkin Lymphoma

  • Test Drug

    Ibrutinib

Participate Sites
3Sites

Terminated3Sites

2018-03-18 - 2024-10-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2008-06-02 - 2009-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB